Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Curis Corporation (CRIS) Common Stock USD0.01

Sell:$1.87 Buy:$1.88 Change: $0.14 (6.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.87
Buy:$1.88
Change: $0.14 (6.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.87
Buy:$1.88
Change: $0.14 (6.75%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Contact details

Address:
128 SPRING STREET, BUILDING C, SUITE 500
LEXINGTON
02421
United States
Telephone:
+1 (617) 5036500
Website:
www.curis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRIS
ISIN:
US2312692005
Market cap:
$110.58 million
Shares in issue:
58.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Martyn Greenacre
    Independent Chairman of the Board
  • James Dentzer
    President, Chief Executive Officer, Director
  • William Steinkrauss
    Chief Financial Officer
  • Robert Martell
    Head - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.